Short review on dopamine agonists: insight into clinical and research studies relevant to Parkinson's disease.
Journal Title: Pharmacological Reports - Year 2005, Vol 57, Issue 6
Abstract
Parkinson's disease (PD) is a chronic and progressive neurological disorder characterized by selective degeneration of dopaminergic neurons (DAergic) in the substantia nigra pars compacta (SNpc) and subsequent decrease in dopamine (DA) levels in the striatum. Although levodopa replacement therapy is initially effective in symptomatic treatment of parkinsonian patients, its effectiveness often declines and various levodopa-related side effects appear after long-term treatment. The disabling side effects of levodopa therapy include motor fluctuations such as the wearing-off or on-off phenomena, dyskinesias and psychiatric symptoms. Nowadays, DA receptor agonists are often regarded as first choice in de novo and young parkinsonian patients to delay the onset of levodopa therapy. In advanced stages of the disease, they are also used as adjunct therapy together with levodopa to retard the development of motor complications. DA receptor agonists mimick the endogenous neurotransmitter, dopamine, and act by direct stimulation of presynaptic (autoreceptors) and postsynaptic DA receptors. Next to their clinical role in treating parkinsonian patients, laboratory studies reported antioxidative and neuron-rescuing effects of DA receptor agonists either in vivo or in vitro. This may involve reduced DA turnover following autoreceptor stimulation and direct free radical scavenging activity. In this review, we focus on and summarize the recently reported effects of the most commonly used DA agonists either in clinical or in research studies relevant to PD treatment.
Authors and Affiliations
Khaled Radad, Gabriele Gille, Wolf-Dieter Rausch
Keywords
Related Articles
- EP ID EP83597
- DOI -
- Views 130
- Downloads 0
Anticonvulsant effect of amiloride in pentetrazole-induced status epilepticus in mice.
Inhibition of sodium hydrogen exchangers (NHE) has been shown to diminish seizure activity in various in vitro and in vivo models of epilepsy. In the present study, we examined the effect of amiloride, a sodium hydrogen...
Lack of the antianxiety-like effect of (S)-3,4-DCPG, an mGlu8 receptor agonist, after central administration in rats.
Substances acting as agonists of group III mGlu receptors were shown to induce an antianxiety-like effect after intrahippocampal administration to rats. The purpose of the present study was to establish whether the selec...
Chronic imipramine treatment reduces inhibitory properties of group II mGlu receptors without affecting their density or affinity.
An increasing body of evidence indicates an important role of the glutamatergic system in the pathophysiology of depression. Not only ionotropic but also metabotropic glutamate receptors (mGlu receptors) have been sugges...
Effect of blockage of the endocannabinoid system by CB(1) antagonism on cardiovascular risk.
The endocannabinoid system is a crucial player in the inflammatory processes underlying atherosclerosis. Recently, basic research studies and animal models have strongly supported the role of the endocannabinoid system n...
Infection and atherosclerosis. An alternative view on an outdated hypothesis.
Already at the beginning of the 20th century, a potential role for microbes in vascular diseases was suggested. However, not until the late '70 of that century, much attention has been paid to this infection hypothesis....